1. Home
  2. Directory
  3. Mississippi
  4. Tupelo
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1992822985

DR. LLOYD PERRY BRITT O. D.
Prescription History 1992822985
Optometrist in Tupelo, MS

NPI Status: Active since March 23, 2007

Contact Information

2270 W MAIN ST STE A
TUPELO, MS
ZIP 38801
Phone: (662) 844-3436

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. LLOYD PERRY BRITT O. D., an active Optometrist specialist practicing in Tupelo, MS. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 149 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 73 claims alone.

Medication Index

Alphagan P

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 21.6
Days Supply 647
MS State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills46.9
Peer Average Days Supply1,312
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.6% less volume than the regional standard for practitioners inside MS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,892.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$492.35

State Avg Cost Per Claim

$331.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Combigan

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 19.6
Days Supply 567
MS State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills67.3
Peer Average Days Supply1,890
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.4% less volume than the regional standard for practitioners inside MS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,116.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$274.46

State Avg Cost Per Claim

$332.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 22
30-Day Fills 42.4
Days Supply 1,270
MS State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills87.0
Peer Average Days Supply2,590
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.1% less volume than the regional standard for practitioners inside MS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $738.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.56

State Avg Cost Per Claim

$25.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 19.7
Days Supply 590
MS State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills150.9
Peer Average Days Supply4,496
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.4% less volume than the regional standard for practitioners inside MS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $302.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.47

State Avg Cost Per Claim

$30.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 73
30-Day Fills 112.7
Days Supply 3,157
MS State Average Benchmarks
Peer Average Claims179.0
Peer Average 30-Day Fills282.1
Peer Average Days Supply7,946
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.2% less volume than the regional standard for practitioners inside MS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,109.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.90

State Avg Cost Per Claim

$14.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 264
MS State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.7
Peer Average Days Supply555
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.1% less volume than the regional standard for practitioners inside MS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $139.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.99

State Avg Cost Per Claim

$13.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. LLOYD PERRY BRITT O. D. provides transparency into local medical care patterns within Tupelo, MS.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.